公开(公告)号：DK59991A

公开(公告)日：1991-04-04

申请号：DK59991

申请日：1991-04-04

Applicant: ABBOTT LAB

Inventor： FUNG ANTHONY K L ,  BAKER WILLIAM R ,  BOYD STEVEN A ,  KEMPF DALE J ,  ARMIGER YOEK-LIN ,  ROSENBERG SAUL H ,  DE BISWANATH ,  PLATTNER JACOB J ,  SHAM HING LEUNG ,  KLEINERT HOLLIS D ,  MANTEI ROBERT A

IPC: A61K31/16 ,  A61K31/19 ,  A61K31/265 ,  A61K31/415 ,  A61K31/4166 ,  A61K31/445 ,  A61K31/4465 ,  A61K31/66 ,  A61P9/00 ,  A61P9/12 ,  A61P43/00 ,  C07C237/08 ,  C07C237/22 ,  C07C317/28 ,  C07C323/57 ,  C07C323/58 ,  C07D203/18 ,  C07D211/44 ,  C07D211/46 ,  C07D211/62 ,  C07D211/96 ,  C07D233/36 ,  C07D233/54 ,  C07D233/56 ,  C07D263/22 ,  C07D295/185 ,  C07D401/12 ,  C07D407/12 ,  C07D413/12 ,  C07D521/00 ,  C07C237/20 ,  C07D205/04 ,  C07D233/64 ,  C07D295/182 ,  C07D405/12 ,  C07K5/06

Abstract: A renin inhibiting compound of the formula: wherein A is a substituent; R1 is hydrogen, loweralkyl, substituted loweralkyl or loweralkenyl; X is CH2, CHOH, C(O), O, S, S(O), SO2, NH, N(O) or -P(O)O-; R3 is loweralkyl, loweralkenyl or substituted loweralkyl; and T is mimic of the Leu-Val cleavage site of angiotensinogen; or a pharmaceutically acceptable salt, ester or prodrug thereof.

公开(公告)号：CA2003382A1

公开(公告)日：1990-05-21

申请号：CA2003382

申请日：1989-11-20

Applicant: ABBOTT LAB

Inventor： KLEINERT HOLLIS D

IPC: C07D211/76 ,  A61K38/00 ,  A61K38/55 ,  A61K45/00 ,  A61P3/08 ,  A61P13/02 ,  A61P15/00 ,  A61P27/02 ,  C07D211/46 ,  C07D417/04 ,  C07D417/06 ,  C07D417/14 ,  C07K5/02 ,  C07K5/078 ,  A61K38/03 ,  A61K31/00 ,  A61K38/05

Abstract: METHOD FOR TREATING VASCULAR DISEASES The present invention relates to the use of renin inhibitors and to renin inhibitor compositions for treating, inhibiting, relieving or reversing vascular diseases including those vascular diseases associated with functional and/or biochemical abnormalities, and in particular peripheral vascular diseases and microvascular diseases associated with diabetes, especially diabetic retinopathy, diabetic nephropathy and diabetic neuropathy. ( 11-1100P/macII-SRC)

公开(公告)号：DK59991D0

公开(公告)日：1991-04-04

申请号：DK59991

申请日：1991-04-04

Applicant: ABBOTT LAB

Inventor： FUNG ANTHONY K L ,  BAKER WILLIAM R ,  BOYD STEVEN A ,  KEMPF DALE J ,  ARMIGER YOEK-LIN ,  ROSENBERG SAUL H ,  DE BISWANATH ,  PLATTNER JACOB J ,  SHAM HING LEUNG ,  KLEINERT HOLLIS D ,  MANTEI ROBERT A

IPC: A61K31/16 ,  A61K31/19 ,  A61K31/265 ,  A61K31/415 ,  A61K31/4166 ,  A61K31/445 ,  A61K31/4465 ,  A61K31/66 ,  A61P9/00 ,  A61P9/12 ,  A61P43/00 ,  C07C237/08 ,  C07C237/22 ,  C07C317/28 ,  C07C323/57 ,  C07C323/58 ,  C07D203/18 ,  C07D211/44 ,  C07D211/46 ,  C07D211/62 ,  C07D211/96 ,  C07D233/36 ,  C07D233/54 ,  C07D233/56 ,  C07D263/22 ,  C07D295/185 ,  C07D401/12 ,  C07D407/12 ,  C07D413/12 ,  C07D521/00 ,  C07C237/20 ,  C07D205/04 ,  C07D233/64 ,  C07D295/182 ,  C07D405/12 ,  C07K5/06

Abstract: A renin inhibiting compound of the formula: wherein A is a substituent; R1 is hydrogen, loweralkyl, substituted loweralkyl or loweralkenyl; X is CH2, CHOH, C(O), O, S, S(O), SO2, NH, N(O) or -P(O)O-; R3 is loweralkyl, loweralkenyl or substituted loweralkyl; and T is mimic of the Leu-Val cleavage site of angiotensinogen; or a pharmaceutically acceptable salt, ester or prodrug thereof.

公开(公告)号：AU4416389A

公开(公告)日：1990-05-01

申请号：AU4416389

申请日：1989-10-03

Applicant: ABBOTT LAB

Inventor： FUNG ANTHONY K L ,  BAKER WILLIAM R ,  ARMIGER YOEK-LIN ,  ROSENBERG SAUL H ,  DE BISWANATH ,  PLATTNER JACOB J ,  BOYD STEVEN A ,  KEMPE DALE J ,  SHAM HING LEUNG ,  KLEINERT HOLLIS D ,  MANTEI ROBERT A

IPC: A61K31/16 ,  A61K31/19 ,  A61K31/265 ,  A61K31/415 ,  A61K31/4166 ,  A61K31/445 ,  A61K31/4465 ,  A61K31/66 ,  A61P9/00 ,  A61P9/12 ,  A61P43/00 ,  C07C237/08 ,  C07C237/22 ,  C07C317/28 ,  C07C323/57 ,  C07C323/58 ,  C07D203/18 ,  C07D211/44 ,  C07D211/46 ,  C07D211/62 ,  C07D211/96 ,  C07D233/36 ,  C07D233/54 ,  C07D233/56 ,  C07D263/22 ,  C07D295/185 ,  C07D401/12 ,  C07D407/12 ,  C07D413/12 ,  C07D521/00 ,  C07D211/48

Abstract: A renin inhibiting compound of the formula: wherein A is a substituent; R1 is hydrogen, loweralkyl, substituted loweralkyl or loweralkenyl; X is CH2, CHOH, C(O), O, S, S(O), SO2, NH, N(O) or -P(O)O-; R3 is loweralkyl, loweralkenyl or substituted loweralkyl; and T is mimic of the Leu-Val cleavage site of angiotensinogen; or a pharmaceutically acceptable salt, ester or prodrug thereof.

公开(公告)号：CA1337909C

公开(公告)日：1996-01-09

申请号：CA615201

申请日：1989-09-29

Applicant: ABBOTT LAB

Inventor： FUNG ANTHONY K L ,  PLATTNER JACOB J ,  BAKER WILLIAM R ,  BOYD STEVEN A ,  ARMIGER YOEK-LIN ,  KEMPF DALE J ,  ROSENBERG SAUL H ,  SHAM HING LEUNG ,  DE BISWANATH ,  KLEINERT HOLLIS D ,  MANTEI ROBERT A

IPC: A61K31/16 ,  A61K31/19 ,  A61K31/265 ,  A61K31/415 ,  A61K31/4166 ,  A61K31/445 ,  A61K31/4465 ,  A61K31/66 ,  A61P9/00 ,  A61P9/12 ,  A61P43/00 ,  C07C237/08 ,  C07C237/22 ,  C07C317/28 ,  C07C323/57 ,  C07C323/58 ,  C07D203/18 ,  C07D211/44 ,  C07D211/46 ,  C07D211/62 ,  C07D211/96 ,  C07D233/36 ,  C07D233/54 ,  C07D233/56 ,  C07D263/22 ,  C07D295/185 ,  C07D401/12 ,  C07D407/12 ,  C07D413/12 ,  C07D521/00

Abstract: A renin inhibiting compound of the formula: wherein A is a substituent; R1 is hydrogen, loweralkyl, substituted loweralkyl or loweralkenyl; X is CH2, CHOH, C(O), O, S, S(O), SO2, NH, N(O) or -P(O)O-; R3 is loweralkyl, loweralkenyl or substituted loweralkyl; and T is mimic of the Leu-Val cleavage site of angiotensinogen; or a pharmaceutically acceptable salt, ester or prodrug thereof.

公开(公告)号：NZ230894A

公开(公告)日：1991-07-26

申请号：NZ23089489

申请日：1989-10-04

Applicant: ABBOTT LAB

Inventor： FUNG ANTHONY K L ,  PLATTNER JACOB J ,  BAKER WILLIAM R ,  BOYD STEPHEN A ,  ARMIGER YOEK-LIN ,  KEMPF DALE J ,  ROSENBERG SAUL H ,  HING LEUNG SHAM ,  DE BISWANATH ,  KLEINERT HOLLIS D ,  MANTEI ROBERT A

IPC: A61K31/16 ,  A61K31/19 ,  A61K31/265 ,  A61K31/415 ,  A61K31/4166 ,  A61K31/445 ,  A61K31/4465 ,  A61K31/66 ,  A61P9/00 ,  A61P9/12 ,  A61P43/00 ,  C07C237/08 ,  C07C237/22 ,  C07C317/28 ,  C07C323/57 ,  C07C323/58 ,  C07D203/18 ,  C07D211/44 ,  C07D211/46 ,  C07D211/62 ,  C07D211/96 ,  C07D233/36 ,  C07D233/54 ,  C07D233/56 ,  C07D263/22 ,  C07D295/185 ,  C07D401/12 ,  C07D407/12 ,  C07D413/12 ,  C07D521/00 ,  C07D405/12 ,  C07D265/30 ,  C07D205/04 ,  C07D207/10 ,  C07D211/48 ,  C07D307/16 ,  C07D317/04 ,  C07D317/14 ,  C07K5/06 ,  C07C215/08 ,  C07C215/12 ,  C07C215/14 ,  C07C229/10 ,  C07C237/06 ,  C07C237/10 ,  C07C237/12 ,  C07C237/14 ,  C07C307/02 ,  C07C311/05 ,  C07C317/24 ,  C07C317/26 ,  C07F7/02 ,  C07F9/22 ,  A61K31/535

Abstract: A renin inhibiting compound of the formula: wherein A is a substituent; R1 is hydrogen, loweralkyl, substituted loweralkyl or loweralkenyl; X is CH2, CHOH, C(O), O, S, S(O), SO2, NH, N(O) or -P(O)O-; R3 is loweralkyl, loweralkenyl or substituted loweralkyl; and T is mimic of the Leu-Val cleavage site of angiotensinogen; or a pharmaceutically acceptable salt, ester or prodrug thereof.